Effectiveness of Generic Versus Reference Cetrorelix Acetate for Ovarian Stimulation Using a Gonadotropin-releasing Hormone（GnRH）Antagonist Protocol in Women Undergoing IVF
Effectiveness of Generic Cetrorelix Acetate Versus Reference Cetrorelix Acetate for Ovarian Stimulation Using a GnRH Antagonist Protocol in Women Undergoing IVF: A Multicenter Non-inferiority, Randomised Controlled Trial
Northwest Women's and Children's Hospital, Xi'an, Shaanxi
1,338 participants
Feb 27, 2024
INTERVENTIONAL
Conditions
Summary
The goal of this clinical trial is to compare the clinical outcomes using different cetrorelix acetate in the context of a GnRH antagonist protocol for ovarian stimulation in women undergoing IVF or intracytoplasmic sperm injection(ICSI) treatment.The main question it aims to answer is whether the generic cetrorelix acetate is non-inferior to the reference product in the GnRH antagonist based protocol for women undergoing IVF. Ovarian stimulation was achieved by several types of follicle-stimulating hormone(FSH) or by FSH combined with luteinizing hormone activity. Daily dose of generic cetrorelix acetate (0.25 mg SC) or original cetrorelix acetate (0.25 mg SC) will be administered when the lead follicle was 14 mm. When more than two follicles reached 17 mm, oocyte maturation was triggered with 250 mcg of recombinant human chorionic gonadotropin.
Eligibility
Inclusion Criteria4
- Infertile couples plan to undergo IVF / ICSI pregnancy treatment into screening procedures and clinical study
- All subjects should sign the informed consent form
- Infertile women <43 years old
- With flexible GnRH antagonist
Exclusion Criteria5
- Subjects could not enter the study if they meet any one of the following criteria
- Preimplantation Genetic Testing (PGT)
- Untreated hydrosalpinges, moderate or severe endometriosis, recurrent spontaneous miscarriage, endometrial pathology, uterine malformations, etc
- Endocrine diseases (such as hyperthyroidism, hyperprolactinemia, etc.) or other systemic disease and other systemic diseases (such as hypertension, diabetes, etc.)．
- Other factors were considered inappropriate by the investigator to participate, or assisted reproductive technology/pregnancy contraindications
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Generic cetrorelix acetate (0.25 mg SC)
reference cetrorelix acetate (0.25 mg SC)
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06023602